z-logo
Premium
Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease
Author(s) -
Wade Janet R.,
Parker Gerry,
Kosutic Gordana,
Feagen Brian G.,
Sandborn William J.,
Laveille Christian,
Oliver Ruth
Publication year - 2015
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/jcph.491
Subject(s) - certolizumab pegol , pharmacokinetics , medicine , population , volume of distribution , pharmacodynamics , covariate , pharmacology , antibody , gastroenterology , area under the curve , immunology , tumor necrosis factor alpha , infliximab , statistics , environmental health , mathematics
Abstract Certolizumab pegol (CZP), an anti–tumor necrosis factor α agent, is an effective therapy for Crohn's disease (CD). A population pharmacokinetic (PK) analysis of subcutaneously administered CZP was performed using data from 2157 CD patients from 9 separate studies. The aim was to determine which covariates influence the disposition of CZP. The final CZP population PK model consisted of a baseline, first‐order absorption, and 1‐compartment disposition. CZP antibodies were treated as a structural model covariate and caused apparent clearance (CL/F) to increase from 0.685 to 2.74 L/day. Body surface area (BSA) influenced both CL/F and apparent volume of distribution (V/F) in a linear fashion; both parameters increased by more than 53% and 49%, respectively, across the range of BSA measurements in the data. Albumin influenced CZP CL/F in a nonlinear fashion; CL/F decreased from 1.05 to 0.613 L/day with increasing albumin concentrations in antibody‐negative patients. C‐reactive protein (CRP) had a borderline influence and CL/F increased by more than 20% across the range of CRP measurements in the data set. Race had a minor influence on V/F. The determined covariates' impact on CZP disposition may be of clinical utility in CZP therapy of CD patients when the PK/pharmacodynamic relationship becomes available.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here